[Form 4] LeMaitre Vascular, Inc. Insider Trading Activity

Rhea-AI Filing Summary

LeMaitre Vascular insider sale summary: George W. LeMaitre, who serves as Chairman and CEO and is a company director, reported a sale of 100,000 shares of LeMaitre Vascular Inc. (LMAT) on 08/06/2025. The sale was executed under a pre-established 10b5-1(c) trading plan adopted on 03/10/2025 and was carried out in multiple trades at a weighted average price of $93.5053, with individual trades ranging from $93.03 to $94.00. After the reported transaction, the reporting person beneficially owned 1,727,003 shares. The filer notes willingness to provide full trade-level details on request. No derivative transactions were reported on this Form 4.

Positive

• Sale executed under a documented 10b5-1(c) plan, reducing ambiguity about timing and intent
• Clear disclosure of trade details: weighted average price $93.5053 and trade range $93.03–$94.00
• Reporting person retains substantial ownership with 1,727,003 shares after the transaction
• Filer offers to provide full trade-level details on request, increasing transparency

Negative

• Insider sold 100,000 shares, which reduces the reporting person's stake in the company
• Sale represents an outflow of shares from an insider; some investors may view insider selling negatively despite plan protections

Insights

Securities Analyst

TL;DR: Insider executed a planned sale under a 10b5-1 plan; transaction appears routine and fully disclosed.

The sale of 100,000 shares was executed under a documented 10b5-1(c) plan, which reduces ambiguity about intent and timing because trades are pre-authorized. The filing discloses the weighted average price of $93.5053 and the trade range $93.03–$94.00, and reports post-transaction ownership of 1,727,003 shares. From a reporting and market-transparency perspective, the disclosure is thorough: the filer offers to provide trade-level details on request and specifies the plan adoption date. There are no reported option or derivative transactions to complicate the disclosure.

Corporate Governance Expert

TL;DR: Governance controls evident; sale executed via an established trading plan, which aligns with best practices for insider transactions.

The Form 4 indicates the transaction was made pursuant to a 10b5-1 plan adopted on 03/10/2025, which generally signals pre-planned liquidity rather than opportunistic insider selling. The filing includes a clear price range and weighted average price and confirms continued substantial beneficial ownership of 1,727,003 shares after the sale. The signer affirms willingness to provide detailed trade information, enhancing transparency. Overall, the disclosure follows regulatory expectations and best-practice governance for executive trading.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

LeMaitre George W

(Last) (First) (Middle)

C/O LEMAITRE VASCULAR, INC.

63 SECOND AVENUE

(Street)

BURLINGTON MA 01803

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
LEMAITRE VASCULAR INC [ LMAT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chairman and CEO

3. Date of Earliest Transaction (Month/Day/Year)
08/06/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/06/2025		S		100,000	D	$93.5053(1)(2)	1,727,003	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Adoption date of referenced 10b5-1(c) plan is: 03-10-2025

2. The price reported in Column 4 is a weighted average price. The transaction was executed in multiple trades ranging from $93.03 to $94.00. The reporting person undertakes to provide to the issuer, any securityholder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares and price at which the transaction was effected.

	/s/ Nathan Ulrich	08/08/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did LeMaitre Vascular (LMAT) report?

The Form 4 reports that Chairman and CEO George W. LeMaitre sold 100,000 shares of LMAT stock.

When was the transaction and under what plan was it executed?

The transaction date is 08/06/2025 and it was executed pursuant to a 10b5-1(c) trading plan adopted on 03/10/2025.

At what price were the shares sold?

The sale was executed in multiple trades at a weighted average price of $93.5053, with trades ranging from $93.03 to $94.00.

How many shares does the reporting person own after the sale?

After the reported transaction the reporting person beneficially owned 1,727,003 shares.

Were there any derivative transactions reported in this filing?

No derivative securities transactions were reported in Table II of this Form 4.